|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/506 | (2006.01) |
| A61K 31/506 | (2013.01) | ||
| A61K 31/551 | (2006.01) | ||
| A61K 45/06 | (2013.01) | ||
| C07D 279/12 | (2006.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61P 35/02 | (2006.01) |
| (11) | Patento numeris | 3334432 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 16835995.8 |
| Europos patento paraiškos padavimo data | 2016-08-12 | |
| (97) | Europos patento paraiškos paskelbimo data | 2018-06-20 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2022-02-23 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2016/046862 |
| Data | 2016-08-12 |
| (87) | Numeris | WO 2017/027829 |
| Data | 2017-02-16 |
| (30) | Numeris | Data | Šalis |
| 201562204400 P | 2015-08-12 | US | |
| 201662342711 P | 2016-05-27 | US |
| (72) |
COFFEY, Gregory , US
FENG, Jiajia , US
|
| (73) |
Portola Pharmaceuticals, Inc. ,
270 East Grand Avenue
Suite 22, South San Francisco, California 94080,
US
|
| (54) | CERDULATINIB FOR TREATING MYELOMA |
| CERDULATINIB FOR TREATING MYELOMA |